Dermatology · Thousand Oaks, CA
NPI
1366418931
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
425 Haaland Dr Ste 204
Thousand Oaks, CA, 91361
Phone (805) 497-8080
Groups this clinician bills Medicare through
Medicare paid, 2024
$176K
4,284 services
Medicare patients, 2024
338
Average age 73
Drug cost, 2024
$161K
436 prescriptions
Company payments, 2025
$6,376
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Azita Simoni was code 17003 (destruction skin lesion), 2,016 times for 243 patients. In total Azita Simoni billed 4,284 services in 47 codes, and Medicare paid $176K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 2,016 | 243 | $5.94 | $12K |
| 17000 Destruction Skin Lesion | Office | 590 | 269 | $33.38 | $20K |
| 99213 Office E&M - Established | Office | 524 | 256 | $69.44 | $36K |
| 17110 Destruction Skin Lesion | Office | 513 | 257 | $93.97 | $48K |
| 99214 Office E&M - Established | Office | 229 | 160 | $101.73 | $23K |
| 99203 Office E&M - New | Office | 67 | 67 | $82.31 | $5,515 |
| 11102 Skin Biopsy | Office | 65 | 61 | $66.70 | $4,336 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 48 | 17 | $0.74 | $35.58 |
| 17111 Destruction Skin Lesion | Office | 26 | 17 | $105.98 | $2,756 |
| 11900 Skin | Office | 25 | 15 | $27.20 | $680 |
| 11103 Skin Biopsy | Office | 20 | 15 | $44.44 | $889 |
| 10060 Skin | Office | 20 | 16 | $105.73 | $2,115 |
| 11602 Skin Lesion Excision | Office | 15 | 14 | $106.92 | $1,604 |
| 13121 Wound Repair - All Levels | Office | 11 | 11 | $359.76 | $3,957 |
By year: 2022 $156K for 3,378 services; 2023 $160K for 3,908 services; 2024 $176K for 4,284 services.
Medicare prescription drug claims, 2024
In 2024, the drug Azita Simoni prescribed most often to Medicare patients was Triamcinolone Acetonide, with 58 prescriptions and refills. In total Azita Simoni wrote 436 Medicare prescriptions that cost $161K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Triamcinolone Acetonide Generic | 58 | 68 | 39 | $809 |
| Doxycycline Hyclate Generic | 31 | 31 | Under 11 | $847 |
| Methylprednisolone Generic | 24 | 24 | 14 | $90.27 |
| Fluorouracil Generic | 21 | 21 | 19 | $1,583 |
| Adapalene Generic | 20 | 22 | Under 11 | $1,278 |
| Hydroxyzine Hcl Generic | 20 | 20 | Under 11 | $67.49 |
| Metronidazole Generic | 19 | 19 | 11 | $1,665 |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | 17 | 17 | 14 | $324 |
| Nystatin-Triamcinolone Nystatin/Triamcinolone Acet | 17 | 19 | 14 | $250 |
| Pimecrolimus Generic | 16 | 18 | Under 11 | $3,178 |
| Hydrocortisone Generic | 15 | 15 | 11 | $52.74 |
| Mupirocin Generic | 12 | 12 | Under 11 | $40.56 |
| Otezla Apremilast | 12 | 12 | Under 11 | $55K |
| Finacea Azelaic Acid | 11 | 15 | Under 11 | $6,418 |
Brand drugs: - claims; generic drugs: 372 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Azita Simoni $6,376 ($6,376 in general payments such as food, travel and fees) from 21 companies. The largest payer was Journey Medical Corporation with $1,609.
| Company | Payments | Amount |
|---|---|---|
| Journey Medical Corporation DERM | 24 | $1,609 |
| Galderma Laboratories, L.P. GALD.SW | 17 | $511 |
| Medimetriks Pharmaceuticals, Inc. | 6 | $483 |
| Lilly USA, LLC LLY | 10 | $415 |
| Abbvie Inc. ABBV | 17 | $396 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 5 | $381 |
| Organon LLC OGN | 6 | $335 |
| UCB, Inc. UCB.BR | 4 | $311 |
| LEO Pharma Inc. | 16 | $286 |
| Incyte Corporation INCY | 18 | $269 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.